BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

PROGRAM

2024 Innovation Forum Agenda

​​

2024 Innovation Forum Agenda

Date July 24-26, 2024

Venue July 24 Room 701AB & 701C, 7F, TaiNEX2
July 25-26 Room 401, 4F, TaiNEX1

Day 1 - Wednesday, July 24
Day 2 - Thursday, July 25
Day 3 - Friday, July 26

09:00 – 10:15

Session 1 (Plenary) – Global Biotech Development

TBD

10:20 – 12:05

Session 2 (Plenary) – Global Biotech Development

Welcome to the conference component of BIO Asia–Taiwan 2024, beginning with two Plenary
Sessions on Global Biotech Development. Hear from representatives of the Biotechnology
Innovation Organization (BIO), discussing biopharma policy and regulatory changes; and US-
based Flagship Pioneering, examining innovative company creation models as well as
collaboration opportunities within Asia. And don’t miss the Tang Prize Lecture; an Exploration of
Biological Diversity, by Feng Zhang, Tang Prize Laureate. In Session 2 we'll dive right into AI in
healthcare, funding and investment strategies, and emerging trends in both the pharmaceutical
industry and in the broader healthcare spaces. Join our esteemed lineup of speakers from Asia
and around the world as they offer their insights on navigating the global biotech landscape.

10:20 – 10:40

Global Biotech Top Trends --- From a US Silicon Valley VC Prospective

Anis Uzzaman, Founder & CEO, Pegasus Tech Ventures, Inc.

10:40 – 11:00

Bioconvergence: how the intersection of biology and technology can advance human health

Paru Deshpande, Vice President R&D, Health Technologies, Imec vzw

11:20 – 11:40

Global trends and Future Opportunities in Pharma

Brian Mi, President, Asia Pacific IQVIA

11:40 – 12:00

Evidence Based Cell and Gene Therapies: Global development for local benefit

Miguel Forte, CEO & Co-Founder, Kiji Therapeutics; President, International Society for Cell & Gene Therapy (ISCT)

12:00 – 12:05

Closing Remarks

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

12:30 – 14:00

Session 3  (Plenary) – Through International Alignment for a Healthier Taiwan

TBD
12:40 – 12:55

Empowering Taiwanese Biomedical Startups through International Collaboration

Lily Wong, Partner, PwC Taiwan

12:55 – 13:10

Establish an Interdisciplinary Collaboration Platform for Biomedical Innovations in Taiwan

Eric Y. Chuang, Vice President,  General Director, Biomedical Technology and Device Research Laboratories, ITRI

14:10 – 15:40

Session 4 – ADC Drug Development and Manufacturing Trends Challenges and Solutions

Antibody-Drug Conjugate (ADC) drugs, while becoming more and more mainstream, still
provide significant manufacturing challenges. This session will examine the latest ADC
development and manufacturing trends such as biomarker-incorporated ADCs, novel payloads,
site-specific conjugation, and novel combination therapies; identify challenges including payload
stability and manufacturing scalability; and consider solutions such as better process
optimization and improved conjugation technologies. Don't miss this deep dive into the world of
ADCs, led by some of the world's leading experts in this field.
14:15 – 14:35

Challenges and Opportunities of ADC Drug Development: Regulatory Considerations

Heidi Wang, CEO, OBI Pharma

14:35 – 14:55

Strategies for Widening the Therapeutic Window

Gur Roshwalb, Partner, aMoon Fund

14:55 – 15:15

Nab2-ADC: Revolutionizing Antibody-Drug Conjugates with Enhanced Targeting and Safety

Gui-Dong Zhu, CEO, SparX Biopharmaceutical Corp.

16:00 – 17:30

Session 5 – Frontier of Gene and Cell Therapies

This session will explore the latest advancements, challenges, and future developments in the
field of gene and cell therapies. Bringing together leading experts, researchers, and clinicians,
we'll provide a comprehensive overview of cutting-edge technologies, such as CRISPR gene
editing, CRT-T and stem cell therapy. We'll highlight current gene and cell therapy applications
as well as the new treatments on the horizon. We'll uncover both drivers and bottlenecks to
progress in this exciting discipline, including challenges from a regulatory, manufacturing, and
ethical perspective. Attendees can expect an invigorating discussion around this rapidly-
evolving topic.
16:03 – 16:20

Overview of Landscape for Cell and Gene Therapies; An update

John Tsai,Executive Partner, Syncona Ltd.

16:20 – 16:40

Driving the next generation of innovative and affordable cell therapies across indications

Alex Shih-Min Huang,VP & Head of Cell Therapy, BeiGene, BeiGene (Taiwan) Limited

16:40 – 16:55

Early Engagement Strategies to Cell and Gene Therapies Up for Success

Chia-Hua Maggie Ho, COO, Amarex Taiwan, LLC. 

16:55 – 17:10

Integration of MSC Value Chain with Enabling Manufacturing Platforms

David Chang, Ph.D., CEO, Taiwan Bio-Manufacturing Corporation (TBMC)

17:10 – 17:25

Investors viewpoint on cell and gene therapy

Gur Roshwalb, Partner, aMoon Fund

17:25 – 17:30

Closing Remarks

09:00 – 10:30

Session 6 – mRNA and New Therapeutic Modalities

This session delves into the transformative potential of mRNA technology in modern
therapeutics. From the pioneering application of mRNA in COVID-19 vaccines, our expert
speakers will highlight advancements in mRNA therapeutics beyond vaccines, including as
personalized cancer treatments, where mRNA can direct the immune system to target and
destroy cancer cells. Additionally, we'll cover the development of mRNA-based therapies for
genetic disorders, such as cystic fibrosis, where mRNA can be used to produce functional
proteins. The latest research on mRNA delivery systems, stability, and manufacturing will also
be covered, addressing the key challenges and future prospects of this promising technology.
Join us to learn how mRNA is revolutionizing the landscape of therapeutic modalities and
paving the way for innovative treatments.
09:05 – 09:25
09:25 – 09:45

Updates for Gene Therapies - an industry perspective

John Tsai, Executive Partner, Syncona Ltd.

09:45 – 10:05

Initiated from Unthinkable with the Optimization (TBD)

Eric Huang, Partner, Delos Capital

10:05 – 10:25

10:35 – 12:15

Session 7 – Taiwan BIO Awards-Successful Stories

TBD
10:35–12:15

Sharing the Experience of Biotech Success
2024 Taiwan BIO Awards Winners:

- Outstanding Company of the Year

Lotus Pharmaceutical Co., Ltd. (美時化學製藥股份有限公司)

Valerie Lau, APAC Chief Commercial Officer

PharmaEssentia Corporation (藥華醫藥股份有限公司)
Albert Qin, Chief Medical Officer

BONRAYBIO CO., LTD. (邦睿生技股份有限公司)
Kevin Chuang, Sales V.P.
 

- Emerging Company of the Year
Pharmosa Biopharm Inc. (國邑藥品科技股份有限公司)
Pei / Kan, President & Cofounder

TSH Biopharm (東生華製藥股份有限公司)
Chuan-Hsu, Chen, Senior Marketing Director

Steminent Biotherapeutics Inc. (仲恩生醫科技股份有限公司)
Wang Lin-Mei, Chairman and CEO

Onyx Healthcare Inc. (醫揚科技股份有限公司)
John Chuang, President

BenQ Dialysis Technology Corp. (明基透析科技股份有限公司)
Spark Huang, Chairman
 

- Startup of the Year

Acepodia, Inc. (英屬開曼群島商育世博股份有限公司)
Sonny Hsiao, CEO & CSO

ImmunAdd Inc. (優億股份有限公司)
Pi-Hui Liang, CEO

Sunhawk Vision Biotech, Inc. (視航生物醫學股份有限公司)
Suh-Hang Hank Juo, President

Elixiron Immunotherapeutics Inc. (安立璽榮生醫股份有限公司)
Hung-Kai Chen, Chairman and Chief Executive Officer

BioGend Therapeutics Co., Ltd. (博晟生醫股份有限公司)
Lee, Po-Wei, Assistant Manager

BRAXX BIOTECH CO., LTD. (貝克生醫股份有限公司)
Vic Chang, CEO

Protect Biotech Inc. (寶泰生醫股份有限公司)
Pearl Fong, Chief R&D Officer
 

- Innovation of the Year

A Novel Ophthalmic Suspension of Clobetasol Propionate derived from APNT Nanoparticle Formulation Technology, USFDA-approved for the Treatment of Inflammation and Pain Following Ocular Surgery (APP13007: 以APNT奈米微粒製劑技術開發並於美國獲准上市之用於治療眼科術後發炎疼痛之丙酸氯倍他索滴眼懸液)
Erick Co, President & CEO, Formosa Pharmaceuticals, Inc.

Influenza Antiviral TG-1000 (流感抗病毒新藥TG-1000)
Li-Wen Chang, Vice President of Clinical Development, TaiGen Biotechnology

Stress EEG Assessment System (憂可視腦波壓力評估系統)
Tina Chang, Executive Assistant to GM, HippoScreen Neurotech Corporation
 

12:25-13:55

Session 8 –Strategic Insights into CMC Program Design: Pioneering Biologics Development Excellence

This will be a deep-dive into Chemistry, Manufacturing, and Controls (CMC) program design, an
essential element of every biologics development facility. We'll explore the latest advancements
and best practices in CMC to ensure the quality, efficacy, and safety of biologics products.
Emphasis will be on developments and practices emerging in Asia, where robust CMC
strategies have accelerated the growth of the region's biopharmaceutical sector. Case studies
will highlight successful CMC frameworks, showcasing advancements in manufacturing
technologies, regulatory harmonization, and cross-border collaborations. Join us to understand
how strategic CMC program design is driving biologics excellence and contributing to the global
success of the biopharmaceutical industry.
12:30 – 12:50

Decoding CMC Program Design: Unveiling the Blueprint for Success in Biologics Development

Friedmund Bachmann, VP CMC, OncoOne Research & Development GmbH

12:50 – 13:10

Drug Bundle-Based ADC Platform: Achieving Site-Specific Conjugation, DAR of 8 or 12, and Dual Payloads

Hsing-Mao Chu, CEO, T-E Meds

13:10 – 13:30

Innovative CMC and Manufacturing Technologies for Next-Generation Bioconjugate Drug Development

Paul Song, CSO, GeneQuantum Healthcare

13:30 – 13:50

Trends in CMC Design for Drug Products: What works and what doesn't

Alan Chang, CEO, Taron Solutions Limited

13:00–15:00

Session 9 – BIO Asia–Taiwan 2024 Opening & Award Ceremony

TBD
13:00-13:30

Admission

13:30-13:35

Introducing Honorable Guests

13:40-13:55

Opening Speech

14:00-14:20

Award Ceremony

• BIO Asia Awards
• 2024 Taiwan BIO Awards

14:20-14:30

Ribbon-cutting Ceremony

14:30

Adjourn

14:30-15:00

VIP Booth Tour

16:00 – 17:30

Session 10 – Translational Medicine, A Journey from Novelty to Commercial Success

This session explores the dynamic field of translational medicine, highlighting its journey
from innovative research to commercial triumph. Delve into the critical elements and processes
that bridge the gap between laboratory discoveries and marketable therapies. Case studies of
recent breakthroughs will illustrate how novel scientific insights are transformed into commercially
viable treatments, addressing unmet medical needs. Topics will include strategic partnerships,
regulatory pathways, scalable manufacturing practices that ensure clinical efficacy and safety,
and an examination of successful funding mechanisms. Attendees will gain valuable knowledge
around navigating the complexities of translational medicine, and will learn how to effectively
translate cutting-edge research into life-changing therapies, driving innovation and improving
patient outcomes.
 
16:05 – 16:25

Understanding Protein Dynamics for Structure-based Drug Design: Design Stories of Crizotinib, Lorlatinib and Repotrectinib

Jingrong Jean Cui, President & CEO, BlossomHill Therapeutics, Inc.
16:25 – 16:45
16:45 – 17:05

Translation Medicine from CMC perspectives, from Preclinical to Commercial

David Chang, Ph.D., CEO, Taiwan Bio-Manufacturing Corporation (TBMC)

09:00 – 10:30

Session 11 – AI for Pharma

With the explosive update of generative artificial intelligence (AI) tools such as ChatGPT across
multiple business domains, AI is one topic you can't afford to ignore. Here we'll explore the
transformative role of AI in the pharmaceutical industry, with a spotlight on its uptake in Asia.
We'll highlight AI's impact on drug discovery and development, showcasing how it can
successfully identify drug candidates, optimize clinical trial designs, and predict drug
interactions. Case studies will demonstrate successful AI integration in the pharmaceutical
industry, and how it's currently driving both innovation and efficiency. Attendees will gain
insights into leveraging AI tools to streamline development pipelines and enhance therapeutic
outcomes. AI is reshaping the pharmaceutical landscape in Asia; be sure to join us to find out
how.
09:05 – 09:20

Improving AI Analytical and Predictive Power in Drug Discovery Through Deep Learning Methodologies and Industry Collaboration

Tom Diethe, Head of The Centre for Artificial Intelligence, AstraZeneca, Cambridge UK
09:20 – 09:35

Unlocking the Potential of AI for High-Throughput Immunotherapy Drug Discovery Through RNA Splicing

Martin Akerman, Co-Founder & CTO, Envisagenics
09:35 – 09:45

Enhancing Drug Discovery with Nuclear Magnetic Resonance & Artificial Intelligence

Thomas Evangelidis, Founder, CEO & CTO, AI|ffinity s.r.o.

09:45 – 09:55

Integrating Artificial Intelligence in the Design and Discovery of Novel Protein Degraders

Shu-Jen Chen, Chief Scientific Officer, AnHorn Medicines Co., Ltd.

09:55 – 10:10

Enable Smart, Data-driven Decisions Through AI in Clinical Development Programs

NaHyun Kim, Ph.D., Solution Sales Specialist, Medidata AI, Dassault SystèmesMedidata

10:45 – 12:15

Session 12– Advances in Genetics and Precision Medicine in Human Diseases

Precision medicine is a discipline that continues to evolve. In this session we'll examine the
latest advancements and applications in this field from a distinguished panel of experts within
both precision medicine and precision health domains. We'll discover how genomic profiling and
personalized treatment strategies are revolutionizing breast cancer care, making a real
difference to patient outcomes. Additionally, we'll highlight breakthroughs in precision
respiratory medicine, such as individualized plans for asthma and chronic obstructive pulmonary
disease (COPD), leveraging genetic and biomarker data. Attendees will gain insights into the
latest research, clinical practices, and future directions in precision medicine and in the wider-
scoped field of precision health. Please join us to learn how precision medicine is transforming
healthcare by providing more personalized and effective treatments.
10:50 – 11:10

Development of Peptide-Based PPI Inhibitor Targeting the BIG3-PHB2 cancer specific complex for Breast Cancer

Toyomasa Katagiri, Director, National Institutes of Biomedical Innovation, Health and Nutrition

11:10 – 11:30

Precision Medicine in Oncology – Today and the Future

John Jiang, Senior Director, Medical & Scientific Affairs, Illumina 

11:30 – 11:50

Development of Precision Respiratory Medicine for chronic inflammation and infection

Kazuhiro Ito, Professor, Imperial College London

12:25 – 13:55

Session 13 – Shaping the Future of Digital Health

As more and more elements of healthcare are encompassed into the ever-growing domain of
digital health, join us over lunch as we delve into the latest trends and business strategies in this
field. We'll examine key trends such as telemedicine, wearable health tech, AI-driven
diagnostics, and personalized health apps. In breaking down digital health's transformative
impact on healthcare delivery, this session will also showcase successful global business
strategies and the companies that are navigating the digital health landscape to drive innovation
and market growth. Our lineup of local and international digital health experts will offer their
insights on how to bridge and expand the cross-disciplinary digital health community.